Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: Current status and future prospects
Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: Current status and future prospects
复制标题
DOI：
10.3748/wjg.v20.i12.3112
复制
发表时间：
2014-03-28
影响因子：
4.3
通讯作者：
Chung, Maxey Ching Ming
中科院分区：
文献类型：
--
作者：
Lee, Seow Chong;Tan, Hwee Tong;Chung, Maxey Ching Ming
肝细胞癌（HCC）是全球癌症死亡的主要原因之一，具有区域特异性病因。尽管在肝癌的诊断方面取得了进步，但由于肝癌的高复发率，肝癌患者的预后仍然很差。目前迫切需要发展预后生物标志物来预测HCC患者在“治愈性”治疗后复发的风险。这种分层可能有助于患者管理和HCC治疗的个性化药物的开发。基于组学的研究促进了以高通量方式研究疾病中生物分子的全局变化，因此很好地准备了解导致HCC复发的复杂变化。从基于组学的研究获得的数据的定量性质允许基于基因、蛋白质和代谢物表达的变化开发预后生物标志物。本文就转录组学、蛋白质组学和代谢组学在肝癌复发研究中的应用作一综述。我们总结了这三个研究领域的文献数据，这些研究声称是HCC复发的预后。我们评论了每个研究领域的局限性以及将研究结果转化为临床应用预测HCC复发所面临的挑战。(C)2014百世登出版集团有限公司有限公司All rights reserved.
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death worldwide, with region specific etiologies. Despite improvements made in the diagnosis of HCC, the prognosis of HCC patients remains poor due to the high recurrence rate of HCC. There is an urgent need for development of prognostic biomarkers to predict the risk of recurrence in HCC patients after "curative" treatment. Such stratification may aid in patient management and development of personalized medicine for HCC treatment. Omics based studies facilitate the study of global changes in biomolecules in a disease in a high throughput manner, and hence are well poised to understand the complex changes which led to HCC recurrence. The quantitative nature of data obtained from omics based studies allow for development of prognostic biomarkers based on changes in gene, protein and metabolite expression. In this review, we surveyed the application of transcriptomics, proteomics and metabolomics in the study of HCC recurrence. We summarised the data in the literature from these three fields of studies that claimed to be prognostic for HCC recurrence. We critiqued on the limitations of each area of research and the challenges faced in translating the research results for clinical application in predicting HCC recurrence. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.